Its compounding advisory committee voted favorably on six peptides: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide, better known as DSIP, did not get one.

What that means is narrower than the headlines. These six moved a step closer to a permanent legal home for pharmacy compounding. It is not FDA approval, and it is not new access.

Access already exists. BPC-157 came off the FDA's Category 2 list in April, and we prescribe it now: a live consultation, history and labs reviewed, a patient-specific prescription, a licensed 503A compounding pharmacy, and a certificate of analysis on every lot. Some of you reading this are on it today. What these six have lacked is durable footing. They sit between the list that barred them and the list that would settle them, which works today and could be revisited tomorrow.

Why that matters: a final rule would make the pathway permanent and let more compounding pharmacies into it. More capacity, more competition, and a firmer floor under everyone practicing this way.

Six peptides got a favorable vote. None of them got approved, and the rule that would make this permanent hasn't been written yet. About four and a half minutes.

If you're skimming: this vote is about durability, not availability. Nothing about current care changes.

Six favorable PCAC recommendations, and the important FDA step that still has to happen.

PCAC advises the FDA. It does not write the final rule. FDA now decides whether to move forward: a proposed rule, public comment, then eventually a final rule. Only then is inclusion on the Bulks List durable, and none of it makes these FDA-approved drugs.

The demand already exists, and a "no" vote does not make it disappear. It pushes people toward websites selling anonymous vials labeled "research use only," where the buyer has no way to confirm identity, purity, potency, sterility, or storage.

Analytical experts at the meeting described tested gray-market products that missed potency targets, carried excessive impurities, or would not have passed a controlled release process.

That is the comparison that matters to me. Not peptides versus no peptides. A prescription, a known source, screening, a rationale, and follow-up, versus a vial and a hope.

If FDA follows the committee, competition could also improve pricing. I would like to see that. It is not automatic.

The evidence varies by peptide and by use. It runs from mechanistic and animal work to international literature, observational data, early trials, and real-world clinical experience.

I also don't think we should pretend years of physician experience count for nothing. Practitioners described favorable outcomes across large numbers of supervised patients. That answers different questions than a controlled trial does. It is still relevant medical experience.

BPC-157 sits in two different conversations, and it helps to keep them apart.

The first is repair: a stubborn tendon, a ligament that hasn't come back, recovery after a soft-tissue procedure. The biology under that involves blood-vessel formation, nitric-oxide signaling, fibroblast migration, and collagen organization.

The second is the gut, specifically an intestinal-barrier problem that is part of a genuinely inflammatory picture rather than occasional bloating. Same molecule, different question, different workup.

KPV is three amino acids. Lysine, proline, valine. That's the whole peptide.

Its mechanism does most of the selecting for us. It appears to quiet NF-κB inflammatory signaling, and oral KPV has an unusual property: inflamed intestinal tissue may take up more of it, through a transporter called PepT1. A compound that concentrates where the tissue is inflamed tells you who it's for. The clearest fit is a patient with inflamed intestinal mucosa after a proper diagnostic workup, with a secondary role in some inflammatory skin conditions.

Small doesn't mean gentle, and it doesn't mean proven. It means specific.

The biology behind the name is thymosin-beta tissue repair: cell migration, inflammation resolution, blood-vessel formation, wound healing. That's why experienced clinicians reach for it in soft-tissue injury and postsurgical recovery, often alongside BPC-157, which is why the two get discussed together.

The question MOTS-c belongs to isn't "how do I recover?" It's "what is this body doing with fuel?"

MOTS-c is encoded inside mitochondrial DNA and tied to AMPK and PGC-1α, the signaling network involved in glucose handling, fat oxidation, energy stress, and metabolic flexibility. The people who make me think about it have insulin resistance, exercise intolerance, deconditioning, or age-related muscle decline.

The limit, plainly: it's a metabolic signal that may support a plan. It doesn't replace training, sleep, or food, and I've never seen it work as a shortcut around any of them.

Someone describes it like this. The focus doesn't hold. Motivation is flat. Names and numbers slip. The fog hasn't lifted since whatever caused it.

That's the conversation Semax belongs in. It's a synthetic analog derived from ACTH(4-10), associated with BDNF, neuroplasticity, and dopamine and serotonin signaling, with a long history of clinical use in Russia and Ukraine. Real experience, not U.S. approval.

It still starts with a neurologic and medical assessment. Brain fog has a differential, and most of it isn't treated with a peptide.

Epitalon is about timing as much as aging. Four amino acids, studied in relation to circadian signaling, melatonin regulation, telomerase, and cellular aging. The clearest fit is a patient whose circadian rhythm is visibly disrupted or whose sleep timing won't stabilize.

This is the one on the list I treat most carefully. Telomerase biology can intersect with cancer biology. Malignancy history and individual risk get screened before Epitalon enters a clinical discussion at all.

Read the full dispatch →

The committee did not approve six new drugs, and it did not switch on anything that was off. What it moved is whether this pathway becomes permanent. The documents that decide that are FDA's proposed rule, the substance definitions inside it, and the final rule that follows comment.

The fine print. This is general education, not a recommendation to obtain or begin any peptide. These substances are not FDA-approved drugs, and the committee recommendations did not immediately change their legal or compounding status. Any use requires an individualized physician evaluation, an appropriate prescription pathway, and ongoing clinical supervision. Kinetic Edge Health provides care in select states.

If you are trying to understand whether an emerging therapy belongs in your plan, begin with a physician evaluation of the goal, the evidence, the alternatives, the risks, and how the response would be monitored.

Short-form dispatches on longevity, metabolic health, and men's performance — from the founder of Kinetic Edge Health.

Physician-led telehealth medical practice. Licensed in select states. Content is educational and does not constitute medical advice. Peptides and compounded medications are prescription items requiring physician evaluation and ongoing clinical oversight.

Privacy · Terms · Telehealth Consent

kineticedgehealth.com · Cleveland, OH

© 2026 Kinetic Edge Health, Inc. · All rights reserved.